A study to evaluate the frequency and the predictive factors of disease activity during the wash-out period after initiation of anti-CD20 monoclonal antibodies in RR-Multiple Sclerosis
Latest Information Update: 04 Jul 2020
At a glance
- Drugs Ocrelizumab (Primary) ; Rituximab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
Most Recent Events
- 04 Jul 2020 New trial record
- 26 May 2020 Results presented at the 6th Congress of the European Academy of Neurology